Naveed B. K. Shams

发表

A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)

Phillip Dinh, Fenghe Lu, A. Chabi, 2021, Journal of glaucoma.

Omidenepag Isopropyl Versus Latanoprost in Primary Open-angle Glaucoma and Ocular Hypertension: ThePhase 3 AYAME Study.

M. Aihara, Naveed B K Shams, Fenghe Lu, 2020, American journal of ophthalmology.

Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

M. Aihara, Naveed B K Shams, Fenghe Lu, 2019, Journal of glaucoma.

DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

L. Damico, N. Ferrara, H. Lowman, 2006, Retina.

Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration.

P. Rosenfeld, J. Heier, G. Hantsbarger, 2006, Ophthalmology.

Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.

M. Blumenkranz, Joan W. Miller, P. Rosenfeld, 2005, Ophthalmology.

Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl.

Naveed B K Shams, Noriko Odani-Kawabata, R. Iwamura, 2018, Journal of medicinal chemistry.

Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.

J. P. Sy, P. Rosenfeld, R. Dreyer, 2006, Ophthalmology.

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.

C. Regillo, T. Ianchulev, David M. Brown, 2008, American journal of ophthalmology.

Efficacy and Safety of Intravitreal Sirolimus for Noninfectious Uveitis of the Posterior Segment: Results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Program.

Q. Nguyen, S. Ohno, P. Merrill, 2020, Ophthalmology.

Intravitreal Sirolimus for Noninfectious Uveitis: A Phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA).

Q. Nguyen, S. Ohno, P. Merrill, 2016, Ophthalmology.

Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study

J. Naor, Q. Nguyen, D. Do, 2013, Journal of Ophthalmic Inflammation and Infection.

Role of vascular endothelial growth factor in ocular angiogenesis.

T. Ianchulev, Naveed B. K. Shams, 2006, Ophthalmology clinics of North America.

Safety of Unoprostone Isopropyl 0.15% Ophthalmic Solution in Patients with Mild to Moderate Asthma

K. Gunawardena, Naveed B K Shams, B. Mertz, 2003, Ophthalmologica.

Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study

M. Aihara, Naveed B K Shams, Fenghe Lu, 2020, Japanese Journal of Ophthalmology.

Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent.

Naveed B K Shams, Noriko Odani-Kawabata, K. Yamamura, 2018, Investigative ophthalmology & visual science.

Unoprostone as adjunctive therapy to timolol: a double masked randomised study versus brimonidine and dorzolamide

A. Hommer, B. Kapik, N. Shams, 2003, The British journal of ophthalmology.

Comparison of the cardiovascular effects of unoprostone 0.15%, timolol 0.5% and placebo in healthy adults during exercise using a treadmill test.

W. C. Stewart, Naveed B K Shams, J. Stewart, 2002, Acta ophthalmologica Scandinavica.

A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data.

J. Nordmann, N. Yannoulis, B. Kapik, 2002, American journal of ophthalmology.

Efficacy of ketotifen fumarate 0.025% ophthalmic solution compared with placebo in the conjunctival allergen challenge model.

M. Abelson, Naveed B K Shams, B. Kapik, 2003, Archives of ophthalmology.

Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys.

M. Fuwa, C. Toris, Naveed B K Shams, 2018, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.